

<Congratulatory Speech>

Greg Perry, Assistant Director General, IFPMA

Currently, IFPMA is the industry interlocutor globally with 50 associations and 40 companies, and focuses on four priority areas: (1) Innovation ecosystem, (2) Global health system, (3) Access to quality medicine and vaccines, and (4) Integrity and ethics. As key regulatory hurdles to delay patient access, we focus on: (1) differences in drug registration procedures by country, (2) lack of GMP convergence, and (3) differences in procedures for Post Approval Changes (PACs). The activities of APAC are considered to help improve these hurdles. As pharmaceutical companies and industry associations, it is important for us to improve access to medicines, to unify regulations, and to have the ability to be responsible for this. APAC has made remarkable evolutions in recent years. We wish for future development.